Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have received an average rating of “Moderate Buy” from the thirteen analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and twelve have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $33.1667.

IMNM has been the subject of several research analyst reports. Stephens lowered their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Leerink Partners decreased their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Truist Financial increased their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Finally, Craig Hallum upped their price target on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $19.81 on Thursday. The company has a fifty day moving average of $22.05 and a 200-day moving average of $21.68. The company has a market capitalization of $2.24 billion, a PE ratio of -8.32 and a beta of 2.04. Immunome has a 52-week low of $7.96 and a 52-week high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, equities analysts forecast that Immunome will post -2.14 EPS for the current fiscal year.

Insider Activity

In other news, CFO Max Rosett sold 65,000 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the transaction, the chief financial officer owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This represents a 54.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 28,200 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $20.65, for a total transaction of $582,330.00. Following the transaction, the director directly owned 341,147 shares in the company, valued at $7,044,685.55. This trade represents a 7.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 139,438 shares of company stock worth $2,964,664. 7.21% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in IMNM. Assetmark Inc. bought a new position in shares of Immunome during the 3rd quarter worth about $39,000. KBC Group NV bought a new position in shares of Immunome during the 1st quarter worth about $60,000. BNP Paribas Financial Markets boosted its position in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio bought a new position in shares of Immunome during the 4th quarter worth about $64,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.